{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:41:56Z","timestamp":1785465716135,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-021-01720-y","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T16:05:13Z","timestamp":1617811513000},"page":"2159-2169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting"],"prefix":"10.1007","volume":"38","author":[{"given":"Moeber","family":"Mahzari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawazen","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"32","key":"1720_CR1","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274.","journal-title":"Eur Heart J"},{"issue":"45","key":"1720_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J"},{"issue":"3","key":"1720_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","volume":"36","author":"B Sjouke","year":"2015","unstructured":"Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36(3):560\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/ehu058.","journal-title":"Eur Heart J"},{"issue":"10","key":"1720_CR4","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1073\/pnas.70.10.2804","volume":"70","author":"JL Goldstein","year":"1973","unstructured":"Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1720_CR5","first-page":"282","volume":"29","author":"MM Al-Nozha","year":"2008","unstructured":"Al-Nozha MM, Arafah MR, Al-Maatouq MA, et al. Hyperlipidemia in Saudi Arabia. Saudi Med J. 2008;29(2):282\u20137.","journal-title":"Saudi Med J"},{"issue":"11","key":"1720_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annepidem.2014.08.001","volume":"24","author":"M Basulaiman","year":"2014","unstructured":"Basulaiman M, El Bcheraoui C, Tuffaha M, et al. Hypercholesterolemia and its associated risk factors\u2014Kingdom of Saudi Arabia, 2013. Ann Epidemiol. 2014;24(11):801\u20138. https:\/\/doi.org\/10.1016\/j.annepidem.2014.08.001.","journal-title":"Ann Epidemiol"},{"key":"1720_CR7","doi-asserted-by":"publisher","first-page":"100667","DOI":"10.1016\/j.ijcha.2020.100667","volume":"31","author":"M Alasnag","year":"2020","unstructured":"Alasnag M, Awan Z, Al Ghamdi A, Al Modaimeigh H, Al SM. Improvement initiative in LDL-C management in Saudi Arabia: a call to action. Int J Cardiol Heart Vasc. 2020;31:100667. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100667.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"1720_CR8","doi-asserted-by":"publisher","first-page":"e102830","DOI":"10.1371\/journal.pone.0102830","volume":"9","author":"AA Alsheikh-Ali","year":"2014","unstructured":"Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS One. 2014;9(8):e102830. https:\/\/doi.org\/10.1371\/journal.pone.0102830.","journal-title":"PLoS One"},{"key":"1720_CR9","doi-asserted-by":"publisher","unstructured":"Al-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, et al. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol. 2018;12(3):685\u201392.e2. https:\/\/doi.org\/10.1016\/j.jacl.2018.02.003.","DOI":"10.1016\/j.jacl.2018.02.003"},{"issue":"36","key":"1720_CR10","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","volume":"36","author":"D Nanchen","year":"2015","unstructured":"Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J. 2015;36(36):2438\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehv289.","journal-title":"Eur Heart J"},{"issue":"1","key":"1720_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1570161116666181005125459","volume":"18","author":"K Al-Rasadi","year":"2020","unstructured":"Al-Rasadi K, Alhabib KF, Al-Allaf F, et al. The Gulf familial hypercholesterolemia registry (Gulf FH): design, rationale and preliminary results. Curr Vasc Pharmacol. 2020;18(1):57\u201364. https:\/\/doi.org\/10.2174\/1570161116666181005125459.","journal-title":"Curr Vasc Pharmacol"},{"issue":"6","key":"1720_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2174\/1570161113666150827125040","volume":"13","author":"A Al-Ashwal","year":"2015","unstructured":"Al-Ashwal A, Alnouri F, Sabbour H, et al. Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a middle east advisory panel. Curr Vasc Pharmacol. 2015;13(6):759\u201370.","journal-title":"Curr Vasc Pharmacol"},{"key":"1720_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.11.008","author":"MA Bamimore","year":"2015","unstructured":"Bamimore MA, Zaid A, Banerjee A, et al. Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry. J Clin Lipidol. 2015. https:\/\/doi.org\/10.1016\/j.jacl.2014.11.008.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1720_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/03014460.2016.1265148","volume":"44","author":"M Fareed","year":"2017","unstructured":"Fareed M, Afzal M. Genetics of consanguinity and inbreeding in health and disease. Ann Hum Biol. 2017;44(2):99\u2013107. https:\/\/doi.org\/10.1080\/03014460.2016.1265148.","journal-title":"Ann Hum Biol"},{"key":"1720_CR15","doi-asserted-by":"publisher","unstructured":"el-Hazmi MA, al-Swailem AR, Warsy AS, al-Swailem AM, Sulaimani R, al-Meshari AA. Consanguinity among the Saudi Arabian population. J Med Genetics. 1995;32(8):623\u20136. https:\/\/doi.org\/10.1136\/jmg.32.8.623.","DOI":"10.1136\/jmg.32.8.623"},{"issue":"2","key":"1720_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4314\/ahs.v14i2.5","volume":"14","author":"AS Warsy","year":"2014","unstructured":"Warsy AS, Al-Jaser MH, Albdass A, Al-Daihan S, Alanazi M. Is consanguinity prevalence decreasing in Saudis?: a study in two generations. Afr Health Sci. 2014;14(2):314\u201321. https:\/\/doi.org\/10.4314\/ahs.v14i2.5.","journal-title":"Afr Health Sci"},{"issue":"1","key":"1720_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygeno.2015.12.001","volume":"107","author":"FA Al-Allaf","year":"2016","unstructured":"Al-Allaf FA, Alashwal A, Abduljaleel Z, et al. Identification of a recurrent frameshift mutation at the LDLR exon 14 (c.2027delG, p.(G676Afs*33)) causing familial hypercholesterolemia in Saudi Arab homozygous children. Genomics. 2016;107(1):24\u201332. https:\/\/doi.org\/10.1016\/j.ygeno.2015.12.001.","journal-title":"Genomics"},{"key":"1720_CR18","doi-asserted-by":"publisher","first-page":"14021","DOI":"10.1038\/hgv.2014.21","volume":"1","author":"FA Al-Allaf","year":"2014","unstructured":"Al-Allaf FA, Athar M, Abduljaleel Z, et al. Identification of a novel nonsense variant c.1332dup, p.(D445*) in the LDLR gene that causes familial hypercholesterolemia. Hum Genome Var. 2014;1:14021. https:\/\/doi.org\/10.1038\/hgv.2014.21.","journal-title":"Hum Genome Var"},{"issue":"1","key":"1720_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gene.2015.03.064","volume":"565","author":"FA Al-Allaf","year":"2015","unstructured":"Al-Allaf FA, Athar M, Abduljaleel Z, et al. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene. 2015;565(1):76\u201384. https:\/\/doi.org\/10.1016\/j.gene.2015.03.064.","journal-title":"Gene"},{"key":"1720_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1874192401711010066","volume":"11","author":"F Alallaf","year":"2017","unstructured":"Alallaf F, Nazar FAH, Alnefaie M, et al. The spectrum of familial hypercholesterolemia (FH) in Saudi Arabia: prime time for patient FH registry. Open Cardiovas Med J. 2017;11:66\u201375. https:\/\/doi.org\/10.2174\/1874192401711010066.","journal-title":"Open Cardiovas Med J"},{"key":"1720_CR21","doi-asserted-by":"publisher","first-page":"RRN1238","DOI":"10.1371\/currents.RRN1238","volume":"3","author":"RM Ned","year":"2011","unstructured":"Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr. 2011;3:RRN1238. https:\/\/doi.org\/10.1371\/currents.RRN1238.","journal-title":"PLoS Curr"},{"issue":"3","key":"1720_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.18388\/abp.2015_1015","volume":"62","author":"KK Alharbi","year":"2015","unstructured":"Alharbi KK, Kashour TS, Al-Hussaini W, et al. Screening for genetic mutations in LDLR gene with familial hypercholesterolemia patients in the Saudi population. Acta Biochim Pol. 2015;62(3):559\u201362. https:\/\/doi.org\/10.18388\/abp.2015_1015.","journal-title":"Acta Biochim Pol"},{"issue":"4","key":"1720_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jsha.2009.10.013","volume":"21","author":"JG Franke","year":"2009","unstructured":"Franke JG, Lansberg PJ. Dutch national screening and disease management program for familial hypercholesterolemia (FH)\u2014a model for Saudi Arabia? J Saudi Heart Assoc. 2009;21(4):259\u201360. https:\/\/doi.org\/10.1016\/j.jsha.2009.10.013.","journal-title":"J Saudi Heart Assoc"},{"issue":"8","key":"1720_CR24","doi-asserted-by":"publisher","first-page":"e0183494","DOI":"10.1371\/journal.pone.0183494","volume":"12","author":"MA Batais","year":"2017","unstructured":"Batais MA, Almigbal TH, Bin Abdulhak AA, Altaradi HB, AlHabib KF. Assessment of physicians\u2019 awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: is there a gap? PLoS One. 2017;12(8):e0183494. https:\/\/doi.org\/10.1371\/journal.pone.0183494.","journal-title":"PLoS One"},{"issue":"6","key":"1720_CR25","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4103\/jfmpc.jfmpc_285_19","volume":"8","author":"MM Arnous","year":"2019","unstructured":"Arnous MM, Alghamdi AM, Ghoraba MA. Assessment of family physicians\u2019 awareness and knowledge of familial hypercholesterolemia in governmental hospitals in Riyadh, Saudi Arabia. J Family Med Prim Care. 2019;8(6):1981\u20136. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_285_19.","journal-title":"J Family Med Prim Care"},{"issue":"1","key":"1720_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12944-020-01266-y","volume":"19","author":"SH Alzahrani","year":"2020","unstructured":"Alzahrani SH, Bima A, Algethami MR, Awan Z. Assessment of medical intern\u2019s knowledge, awareness and practice of familial hypercholesterolemia at academic institutes in Jeddah, Saudi Arabia. Lipids Health Dis. 2020;19(1):101. https:\/\/doi.org\/10.1186\/s12944-020-01266-y.","journal-title":"Lipids Health Dis"},{"issue":"20","key":"1720_CR27","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.jacc.2020.03.058","volume":"75","author":"JJP Kastelein","year":"2020","unstructured":"Kastelein JJP, Reeskamp LF, Hovingh GK. Familial hypercholesterolemia: the most common monogenic disorder in humans. J Am Coll Cardiol. 2020;75(20):2567\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.058.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1720_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"s1","key":"1720_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0735-1097(02)81012-9","volume":"39","author":"C Gagne","year":"2002","unstructured":"Gagne C, Gaudet D, Bruckert E, et al. Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia. J Am Coll Cardiol. 2002;39(s1):227. https:\/\/doi.org\/10.1016\/S0735-1097(02)81012-9.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1720_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-2004-822985","volume":"4","author":"AD Marais","year":"2004","unstructured":"Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Sem Vasc Med. 2004;4(1):43\u201350. https:\/\/doi.org\/10.1055\/s-2004-822985.","journal-title":"Sem Vasc Med"},{"issue":"20","key":"1720_CR31","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","volume":"124","author":"FJ Raal","year":"2011","unstructured":"Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.042523.","journal-title":"Circulation"},{"issue":"12","key":"1720_CR32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1172\/JCI18925","volume":"111","author":"DJ Rader","year":"2003","unstructured":"Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111(12):1795\u2013803. https:\/\/doi.org\/10.1172\/JCI18925.","journal-title":"J Clin Invest"},{"issue":"10","key":"1720_CR33","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/lt.24803","volume":"23","author":"M Al Sebayel","year":"2017","unstructured":"Al Sebayel M, Abaalkhail F, Al Abbad S, et al. Liver transplantation in the Kingdom of Saudi Arabia. Liver Transpl. 2017;23(10):1312\u20137. https:\/\/doi.org\/10.1002\/lt.24803.","journal-title":"Liver Transpl"},{"issue":"4","key":"1720_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","volume":"11","author":"C Stefanutti","year":"2017","unstructured":"Stefanutti C, Julius U, Watts GF, et al. Toward an international consensus\u2014integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol. 2017;11(4):858\u2013713. https:\/\/doi.org\/10.1016\/j.jacl.2017.04.114.","journal-title":"J Clin Lipidol"},{"key":"1720_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.atherosclerosissup.2014.07.006","volume":"15","author":"E Bruckert","year":"2014","unstructured":"Bruckert E, Saheb S, Bont\u00e9 JR, Coudray-Omn\u00e8s C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey. Atheroscler Suppl. 2014;15:46\u201351.","journal-title":"Atheroscler Suppl"},{"issue":"Suppl","key":"1720_CR36","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172\u20137. https:\/\/doi.org\/10.1194\/jlr.R800091-JLR200.","journal-title":"J Lipid Res"},{"key":"1720_CR37","doi-asserted-by":"crossref","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Trial evaluating evolocumab, a PCSK9 antibody in patients with homozygous FH (TESLA): results of the randomised, double-blind placebo-controlled trial. European Atherosclerosis Society; Madrid, Spain; 2014. Abstract 1177.","DOI":"10.1016\/j.atherosclerosis.2014.05.004"},{"issue":"9965","key":"1720_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(14)61374-X.","journal-title":"Lancet"},{"issue":"33","key":"1720_CR39","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","volume":"35","author":"EA Stein","year":"2014","unstructured":"Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014;35(33):2249\u201359. https:\/\/doi.org\/10.1093\/eurheartj\/ehu085.","journal-title":"Eur Heart J"},{"issue":"19","key":"1720_CR40","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","volume":"128","author":"EA Stein","year":"2013","unstructured":"Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113\u201320. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004678.","journal-title":"Circulation"},{"issue":"1","key":"1720_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","volume":"71","author":"M Ogura","year":"2018","unstructured":"Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1\u20137. https:\/\/doi.org\/10.1016\/j.jjcc.2017.07.002.","journal-title":"J Cardiol"},{"key":"1720_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30044-X","author":"FJ Raal","year":"2017","unstructured":"Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017. https:\/\/doi.org\/10.1016\/S2213-8587(17)30044-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1720_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa061189","volume":"356","author":"M Cuchel","year":"2007","unstructured":"Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148\u201356. https:\/\/doi.org\/10.1056\/NEJMoa061189.","journal-title":"N Engl J Med"},{"issue":"3","key":"1720_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","volume":"136","author":"DJ Blom","year":"2017","unstructured":"Blom DJ, Averna MR, Meagher EA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136(3):332\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028208.","journal-title":"Circulation"},{"issue":"9860","key":"1720_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(12)61731-0.","journal-title":"Lancet"},{"issue":"4","key":"1720_CR46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacl.2015.05.001","volume":"9","author":"J Roeters van Lennep","year":"2015","unstructured":"Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide. J Clin Lipidol. 2015;9(4):607\u201317. https:\/\/doi.org\/10.1016\/j.jacl.2015.05.001.","journal-title":"J Clin Lipidol"},{"key":"1720_CR47","unstructured":"Aegerion Pharmaceuticals Inc. Juxtapid prescribing information. 2013."},{"key":"1720_CR48","unstructured":"Amryt Pharmaceuticals DAC. Lojuxta summary of product characteristics. 2015."},{"issue":"Suppl","key":"1720_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0735-1097(20)32619-X","volume":"11","author":"J Underberg","year":"2020","unstructured":"Underberg J, Cannon C, Larrey D, Makris L, Phillips H, Blom D. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the lomitapide observational worldwide evaluation registry (LOWER). J Am Coll Cardiol. 2020;11(Suppl):1. https:\/\/doi.org\/10.1016\/S0735-1097(20)32619-X.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"1720_CR50","doi-asserted-by":"publisher","first-page":"S588","DOI":"10.1016\/S0168-8278(18)31438-7","volume":"68","author":"D Larrey","year":"2018","unstructured":"Larrey D, Underberg J, Cannon C, Makris L, Jurecka A, Blom D. Long-term liver safety of lomitapide in patients with homozygous familial hypercholesterolemia: three-year data from the lomitapide observational worldwide evaluation registry (LOWER). J Hepatol. 2018;68(Suppl. 1):S588.","journal-title":"J Hepatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01720-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T03:45:18Z","timestamp":1620618318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01720-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}